if rejected by fda, here is the outcome ...
=== If the FDA rejects eteplirsen, Sarepta probably won't be able to refile a regulatory application of any kind for at least three years, and that scenario implies a heavy dose of dilutive financing in the interim.
giving all gain last friday and more = ouch
but i like it at deep on sale price for a quick trade
=== On the downside, Chinese search engine Baidu (BIDU) sold off hard, falling nearly 8% to 179.26 in huge volume on news that the Chinese government will investigate the Beijing-based firm over the apparent death of a young man who sought to find information at Baidu’s flagship site to look for potential treatments for his rare cancer.
The stock gave back all of Friday’s gains and more following Q1 results, which showed a 16% drop in Q1 profit despite a 19% revenue increase. It marked Baidu’s second year-over-year EPS decline in three quarters, while revenue growth slowed for a third quarter in a row. Revenue climbed 38%, 31% and 27% in the prior three periods.
gotta sell after rosy ER +10% gain last friday
today all profit just went kaput due to bad news
watching watching at stock got slapped -8% haircut today
down down down = no approval from ms. fda director and company
i no longer have the stock so rooting for stock to be down heheheeh